Toothpick..please readPlease do not take this as criticism but you have been posting some statements that are wrong. If you go back and read the 6th Data Safety Committee report 17/ 11/08 {Bionche web site} you will see that hidden way down after all the positive statements is the line" A significant proportion of patients.....etc." They basically screwed up the trial with many? patients whose cancer did not qualify for inclusion in the trial set...I wrote at the time that they should come clean and tell us exactly where we stood..I guess Jennifer was not allowed to ...For all we know we could have been starting almost from scratch again..I honestly believe that there was some prior knowledge as to this diagnosis problem as they had just added 7 more sites to the trial...I also believe this was pivital in potential suitors packing there bags and walking out...As you recall up to that point Bioniche was demanding that it be lead in the trial. I believe at that time I wrote something to the fact that ..if you were going to put up millions of your company's dollars would you want the success depending on someone who could not even get the initial qualifiction diagnosis right..As events have played out Bioniche has finally been forced to take a back seat in the trial. I am comfortable with this as now we are playing in a higher league and the costs are minimal. By the way the patients who were treated but disqualified for the trial were still carried for ethical and moral consideration...Hopefully a study of these results might lead to future endeavors...The trial results are for a 1 year follow up after treatment...If you notice they have up to now used the word enrollment. Hopefully they are the same and that there are no more disqualifications. I'm sorry I didn't speak up sooner regarding the 2/3 enrollment but I kept thinking I already had made my point and that surely someone else would speak up.. This company has huge potential but also a history of overstatement and screw-ups...They missed forecasts and their performance to date has not created confidence or value for their investors. My bet is that that was the old Bioniche. They now have a fairly clean balance sheet , a partner with deep pockets and history, and a load of potential in differing fields..If they can regain a little cedibility with the investment community and live up to their own expectations , I believe we will feel the long wait was worth it. Next spring will reveal mcc's potential..I'm not expecting a blockbuster just a better than and safer treatment...Dusty11